Rogala, Sandra
Ali, Tamer
Melissari, Maria-Theodora
Währisch, Sandra
Schuster, Peggy
Sarre, Alexandre
Emídio, Rebeca Cordellini
Boettger, Thomas http://orcid.org/0000-0003-4280-8449
Rogg, Eva-Maria
Kaur, Jaskiran
Krishnan, Jaya
Dumbović, Gabrijela
Dimmeler, Stefanie http://orcid.org/0000-0002-1045-2436
Ounzain, Samir
Pedrazzini, Thierry http://orcid.org/0000-0002-7969-8725
Herrmann, Bernhard G. http://orcid.org/0000-0002-2192-8188
Grote, Phillip http://orcid.org/0000-0002-9254-1458
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (Exc147-2, 403584255, 403584255, 403584255, GR 4745/1-1, Exc147-2, 403584255, 403584255, 390649896, 403584255)
Max-Planck-Gesellschaft
Article History
Received: 27 July 2023
Accepted: 19 October 2023
First Online: 2 November 2023
Competing interests
: The authors declare the following financial interest; S.O. is currently the CEO and shareholder of HAYA Therapeutics. HAYA is developing ASO-based drugs to target lncRNAs in heart disease. S.O. declares non-financial competing interests. The other authors declare no competing interest.